Moderna stock rally could surge after cancer vaccine data
Moderna’s shares have jumped 650% this year, and a late‑stage melanoma vaccine trial showing a 42% risk reduction could push the rally even higher, analysts say.
Topic
biotech
The latest biotech news, explained clearly: what happened, why it matters and what comes next. Every NewsClearly story on biotech, newest first.
1 story